Moscow, January 4th – The efficacy of the Russian vaccine for melanoma therapy exceeds 90 percent, stated on Saturday the director of the Gamaleya National Research Center for Epidemiology and Microbiology, Alexander Gintsburg.
"Preclinical studies in animals have already concluded; the efficacy is high and surpasses 90 percent. If we refer to the disappearance of the main tumor mass, we could speak of 100 percent, and in the case of metastases, 90 percent," said Gintsburg.
He also mentioned that the first patients will begin receiving this vaccine in early 2026.
Previously, the Minister of Health of the Russian Federation, Mikhail Murashko, declared that the ministry gave its approval to use the NEOONKOVAK vaccine for melanoma therapy in clinical practice.
The medication was jointly developed by the Gamaleya Center and the Blochin National Cancer Research Center. The manufacturer is the National Scientific Center of Radiology.
(Information from Prensa Latina)
